SEMHF:OTC-Siemens Healthineers AG (USD)

COMMON STOCK | Medical Devices |

Last Closing

USD 54.0515

Change

-3.35 (-5.83)%

Market Cap

USD 67.12B

Volume

4.33K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-19 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
ABT Abbott Laboratories

-0.37 (-0.35%)

USD 184.43B
SYK Stryker Corporation

-1.49 (-0.45%)

USD 133.55B
MDT Medtronic PLC

+0.03 (+0.04%)

USD 112.28B
BSX Boston Scientific Corp

-0.18 (-0.25%)

USD 106.14B
EW Edwards Lifesciences Corp

+0.76 (+0.90%)

USD 55.80B
ZBH Zimmer Biomet Holdings Inc

-1.10 (-0.92%)

USD 26.16B
STE STERIS plc

+1.20 (+0.59%)

USD 21.09B
PHG Koninklijke Philips NV ADR

-0.20 (-0.75%)

USD 18.20B
SNN Smith & Nephew SNATS Inc

+0.30 (+1.24%)

USD 10.70B
BIO Bio-Rad Laboratories Inc

+5.25 (+1.92%)

USD 7.97B

ETFs Containing SEMHF

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -6.97% 57% F 22% F
Dividend Return 1.74% 89% A- 75% C
Total Return -5.22% 60% D- 24% F
Trailing 12 Months  
Capital Gain -5.02% 61% D- 27% F
Dividend Return 1.78% 67% D+ 26% F
Total Return -3.24% 61% D- 24% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 8.33% 58% F 67% D+
Dividend Return 8.77% 55% F 62% D
Total Return 0.45% 20% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 23.35% 76% C+ 49% F
Risk Adjusted Return 37.58% 76% C+ 61% D-
Market Capitalization 67.12B 86% B+ 96% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Dividend Growth

This stock has shown below median dividend growth in the previous 5 years compared to its sector.